$3.52
+0.01 (+0.28%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where GALT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional · 5 with posted results
Held by 6 tracked-famous managers (MARSHALL WACE, LLP, TWO SIGMA INVESTMENTS, LP, CITADEL ADVISORS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, RENAISSANCE TECHNOLOGIES LLC, +1 more) · FINRA short interest 23.6 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 7 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH CirrhosisNCT04365868results2026-06-30Proportion of Patients in the Belapectin Treatment Groups Who Develop New Esophageal Varices at 78 Weeks [18 Months] of Treatment Compared to PlaceboRandomized · Double-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Terminatedsponsor's stated reason: Based on FDA feedback, Stage 1 of NAVIGATE was analyzed as a stand-alone trial. Study was not prematurely terminated for safety reasons. | Drug: belapectin, Placebo | Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis | 357 | 2025-03-11actual | 2026-06-30 |
| GT-032 Belapectin Hepatic ImpairmentNCT04332432results2026-07-14To Assess the PK AUC0-∞ of Belapectin Following a Single IV Dose of Belapectin in Subjects With Mild, Moderate, or Severe Hepatic Impairment, Compared to Healthy Subjects With Normal Hepatic Function.Non-randomized · Open-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: belapectin | Hepatic Impairment | 38 | 2022-03-09actual | 2026-07-14 |
| An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of PsoriasisNCT02407041results2020-09-07Number of Participants With PASI-75, or a 75% Improvement From Baseline in PASI ScoreOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: GR-MD-02 | Psoriasis | 5 | Mar 2018actual | 2020-09-07 |
| Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash CirrhosisNCT02462967results2020-10-08Change in Portal Pressure at Year 1 (Change in HVPG From Baseline and 1 Year)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: GR-MD-02, Placebo | Hypertension, Portal | 162 | Oct 2017actual | 2020-10-08 |
| Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced FibrosisNCT02421094results2020-09-28Mean Change in Liver Fibrosis of Corrected T1 (cT1) Mapping (LiverMultiScan -LMS)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: GR-MD-02, Placebo | Nonalcoholic Steatohepatitis | 30 | 2016-09-27actual | 2020-10-08 |
| Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced FibrosisNCT01899859Primary objective is to characterize safety for GR-MD-02 administered intravenously to subjects w/ biopsy-proven NASH w/ advanced liver fibrosis. Specifically assessed by number of subjects experiencing TEAEs.Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: GR-MD-02, Placebo | Non-Alcoholic Steatohepatitis (NASH) | 31 | Feb 2015actual | 2015-02-23 |
| Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder CancerNCT00386516Objective response rate (ORR) defined as complete response (CR) rate plus partial response (PR) rate using Response Evaluation Criteria in Solid Tumors (RECIST)Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Financing and re-organization | Drug: GM-CT-01, 5-Fluorouracil | Cancer of the Bile Duct, Gallbladder Cancer | 0 | Jun 2009actual | 2017-08-01 |
| A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal CancerNCT00388700Primary Outcomes: Assess the efficacy and safety of GM-CT-01 administered with 5-FU, LV, and Avastin® in the first-line treatment of unresectable, locally advanced, and/or metastatic CRC.Open-label · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Financing and re-organization | Drug: GM-CT-01, 5-Fluorouracil, Leukovorin, bevacizumab | Colorectal Cancer | 0 | Jun 2009actual | 2018-02-14 |
| GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal CancerNCT00110721frequency of objective complete or partial tumor responseOpen-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Study protocol amended to a new treatment regimen: study DAVFU-006. | Drug: GM-CT-01 plus 5-Fluorouracil | Colorectal Cancer | 20 | Jun 2007actual | 2012-03-06 |
| Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid TumorsNCT00054977SafetyOpen-label · Treatment | Phase 1 | Completed | Drug: GM-CT-01, 5-fluorouracil | Colorectal Cancer, Lung Cancer, Breast Cancer, Head and Neck Cancer, Prostate Cancer | 40 | Apr 2005actual | 2012-03-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19